The Bethesda criteria, on the other hand, identify individuals with CRC or other LS tumors who should have their cancers tested for evidence of MMR deficiency using IHC and/or MSI 16, and if deficiency is identified, MMR germline mutation testing is warranted. Here, MRC1 is linked to Leigh syndrome.